02.12.2025
Where science meetssoftware.
Software as treatment.
Delivered to your phone.
Prescribed by your physician.
Click Therapeutics is redefining modern medicine with patient-centric digital treatments. Operating at the intersection of biology and technology, Click combines neuroscience with the power of software, creating a new way to treat disease.
Digital treatments, tangible outcomes.
We develop, validate, and commercialize software as prescription medical treatments for people with unmet medical needs.
Medicine just got a digital upgrade: Software-Enhanced Drugs™
Click SE™ solutions combine software with pharmacotherapy to create software-enhanced drug™ treatments, designed to deliver added clinical benefit to patients compared to drug alone.
One powerful platform. Many ways to treat disease.
Our multimodal, platform-based approach targets disease and drives outcomes from multiple different angles, combining scientifically proven therapies with proprietary neuromodulatory mechanisms of action to deliver clinically-meaningful interventions.
Latest at Click
Recent publications
Collaborators
By embracing collaborations that build on our unique areas of expertise, we’re powering a new era of medicine.
Contact
Stay up to date with news and updates
Click Therapeutics Today
In numbers
Upcoming event
Apr30Speaker:
David Benshoof Klein
Founder & CEO
Business Design Centre
London
Products Pipeline
Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States
Click Therapeutics is pleased to announce FDA marketing authorization for CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in the United States. FDA marketing authorization for CT-132 is supported by data from both the pivotal ReMMi-D randomized controlled trial, in which CT-132 met its primary endpoint by significantly reducing monthly migraine days on top of background pharmacotherapy, and the bridging study, ReMMiD-C, where CT-132 showed similar performance in patients on calcitonin gene-related peptide (CGRP) inhibitors.
CT-132 combines scientifically proven therapies with proprietary mechanisms of action to deliver clinically-meaningful interventions for patients with episodic migraine. Intended for adjunctive use alongside other treatments for migraine, CT-132 demonstrated in clinical testing the ability to add clinically meaningful benefit on top of background pharmacotherapy.
In numbers
Upcoming event
Apr30Speaker:
David Benshoof Klein
Founder & CEO
Business Design Centre
London
Products Pipeline
Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States
Click Therapeutics is pleased to announce FDA marketing authorization for CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in the United States. FDA marketing authorization for CT-132 is supported by data from both the pivotal ReMMi-D randomized controlled trial, in which CT-132 met its primary endpoint by significantly reducing monthly migraine days on top of background pharmacotherapy, and the bridging study, ReMMiD-C, where CT-132 showed similar performance in patients on calcitonin gene-related peptide (CGRP) inhibitors.
CT-132 combines scientifically proven therapies with proprietary mechanisms of action to deliver clinically-meaningful interventions for patients with episodic migraine. Intended for adjunctive use alongside other treatments for migraine, CT-132 demonstrated in clinical testing the ability to add clinically meaningful benefit on top of background pharmacotherapy.